Obesity Today—May 12, 2026

LucidQuest

4 weeks ago

This week’s Obesity update highlights regulatory actions, access shifts, clinical delivery innovation, funding activity, and commercial momentum.

In this Newsletter

Dive deeper

💊 IMCIVREE acquired HO launch and Japan review [1] [US, EU, Japan • 05 May 2026]

https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-reports-first-quarter-2026-financial
Context: Rhythm Pharmaceuticals reported Q1 2026 results and updates for IMCIVREE (setmelanotide) in acquired hypothalamic obesity.
Key point: Company said FDA approval came on 19 Mar 2026, EC authorization came on 01 May 2026, and Japan PMDA review is underway.
Implication: May influence prescriber choice and payer reviews pending full data.

📈 Zealand Pharma obesity pipeline funding update [2] [07 May 2026]

https://www.marketscreener.com/news/zealand-pharma-posts-smaller-than-expected-q1-loss-as-obesity-drugs-advance-ce7f58d3d988f320
Context: Zealand Pharma reported Q1 results and discussed obesity assets including petrelintide and survodutide.
Key point: Company announced a share buyback, expected Roche milestone payments, and maintained 2026 operating expense guidance.
Implication: Signals pipeline investment and modality expansion.

🧬 Daewoong adds once-monthly semaglutide program [3] [Korea • 08 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31574
Context: Daewoong Pharmaceutical partnered with Tionlab Therapeutics on a long-acting GLP-1 obesity treatment.
Key point: Partners filed a Phase 1 IND in Korea for a once-monthly semaglutide injection and plan first dosing this year.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

❄️ Sedivention funds obesity cryo-ablation device [4] [Germany • 09 May 2026]

https://www.tamradar.com/funding-rounds/sedivention-seed-2-9m
Context: Sedivention is developing Blizzard Catheter, an outpatient cryo-ablation device targeting gastric vagus nerve trunks.
Key point: Company raised €2.9 million in seed funding to support product development, first-in-human studies, and regulatory preparation.
Implication: Signals pipeline investment and modality expansion.

🇨🇳 Novo sees China Ozempic generic delay [5] [China • 06 May 2026]

https://www.swissinfo.ch/eng/novo-sees-generic-ozempic-delayed-in-china-until-next-year/91373533
Context: Semaglutide patent protection for Ozempic and Wegovy expired in China in March 2026.
Key point: Novo Nordisk said Ozempic is entitled to regulatory data protection in China until April 2027.
Implication: Introduces competition that may affect pricing and formulary access.

💊 Novo and Lilly oral GLP-1 uptake [6] [US • 07 May 2026]

https://www.reuters.com/business/healthcare-pharmaceuticals/novo-lilly-gain-signs-weight-loss-pills-could-expand-market-2026-05-07/
Context: Reuters reported early uptake for Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo pill.
Key point: Investors and analysts said oral GLP-1s may expand the market by reaching patients who avoid injections.
Implication: May influence prescriber choice and payer reviews pending full data.

🏥 Wegovy Medicare GLP-1 Bridge access [7] [US • 07 May 2026]

https://www.prnewswire.com/news-releases/wegovy-access-expanded-for-medicare-beneficiaries-living-with-obesity-through-the-medicare-glp-1-bridge-starting-july-1-2026-302764949.html
Context: Novo Nordisk announced Wegovy access for eligible Medicare beneficiaries through the Medicare GLP-1 Bridge.
Key point: Program is set to begin 01 Jul 2026 with access to Wegovy injection and tablets for eligible patients.
Implication: May expand screening, initiation, and follow-up at scale.

⚖️ Novo and Lilly fined in France over promotion [8] [France • 06 May 2026]

https://www.fiercepharma.com/marketing/novo-nordisk-eli-lilly-fined-french-regulators-over-obesity-drug-promotions Context: ANSM reviewed obesity awareness campaigns from Novo Nordisk and Eli Lilly.
Key point: French regulator fined Novo and Lilly, saying campaigns risked being understood as prescription drug promotion.
Implication: Introduces competition that may affect pricing and formulary access.

🏆 Mounjaro reported as top-selling drug [9] [Global • 08 May 2026]

https://www.globalcosmeticsnews.com/lillys-mounjaro-becomes-worlds-best-selling-drug/
Context: Report compared Eli Lilly’s Mounjaro sales with Merck’s Keytruda sales in Q1 2026.
Key point: Source reported Mounjaro surpassed Keytruda as the world’s top-selling pharmaceutical product.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Oral GLP-1 launches could widen obesity treatment adoption beyond patients comfortable with injections.
Payer and access moves, including Medicare GLP-1 Bridge, may shape real-world uptake in older US patients.
China data protection and France promotion enforcement show commercial growth is tightly linked to regulatory rules.
Device and long-acting delivery programs highlight interest in alternatives to weekly injectable GLP-1s.
Rare obesity treatment momentum continues through IMCIVREE approvals and Japan review.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Obesity archive on our research hub page

🎯 Catch up on the Top Obesity news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What changed for IMCIVREE (Rhythm Pharmaceuticals) in acquired hypothalamic obesity?

Rhythm said IMCIVREE received US approval on 19 Mar 2026 and EC authorization on 01 May 2026. Japan PMDA review is underway, with a decision anticipated in H2 2026. [1]

What is Zealand Pharma highlighting in obesity?

Zealand discussed petrelintide and survodutide, plus expected Roche milestone payments and a buyback. The company said it would not compromise on R&D investment. [2]

What is Daewoong developing with Tionlab Therapeutics?

Daewoong and Tionlab are developing a once-monthly semaglutide injection for obesity. The partners filed a Phase 1 IND in Korea and plan first patient dosing this year. [3]

What is Sedivention’s Blizzard Catheter?

Blizzard Catheter is a proposed outpatient cryo-ablation device targeting gastric vagus nerve trunks to reduce hunger signals. Seed funding will support development and first-in-human studies. [4]

Why does Novo Nordisk expect China Ozempic generics to be delayed?

Novo said Ozempic has regulatory data protection in China until April 2027 under the China–Switzerland Free Trade Agreement. [5]

Why were Novo Nordisk and Eli Lilly fined in France?

ANSM said obesity awareness campaigns could be interpreted as promoting prescription medicines to the public, even when products were not named. [8]

Entities / Keywords

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, acquired hypothalamic obesity, HO, TRANSCEND, PMDA, FDA, European Commission
Zealand Pharma, petrelintide, survodutide, Roche, Boehringer Ingelheim
Daewoong Pharmaceutical, Tionlab Therapeutics, semaglutide, Quject Sphere, CURE microsphere, GLP-1
Sedivention, Blizzard Catheter, cryo-ablation, vagus nerve, obesity medtech
Novo Nordisk, Ozempic, Wegovy, semaglutide, Medicare GLP-1 Bridge, ANSM
Eli Lilly, Mounjaro, Zepbound, Foundayo, tirzepatide, oral GLP-1
Merck, Keytruda, oncology, patent expiry